Moleculin Biotech Inc (MBRX): Short covering should begin now bringing...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	2
Posts	453
Boards Moderated	0
Alias Born	10/07/2017

RealLovePipes

Re: None

Wednesday, 04/24/2019 2:33:52 PM

Wednesday, April 24, 2019 2:33:52 PM

Short covering should begin now bringing this to near or at $2 by ph

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent MBRX News

Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 12:35:16 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 12:30:17 PM
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial • PR Newswire (US) • 08/01/2024 12:30:00 PM
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/30/2024 11:00:46 AM
Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/22/2024 09:31:38 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 12:30:31 PM
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML • PR Newswire (US) • 07/10/2024 12:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 09:00:44 PM
Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 12:00:40 PM
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial • PR Newswire (US) • 06/14/2024 12:00:00 PM
Moleculin to Present at the Virtual Investor Pitch Conference • PR Newswire (US) • 06/12/2024 01:00:00 PM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/07/2024 09:05:48 PM
Moleculin to Participate in the Virtual Investor Lunch Break Series • PR Newswire (US) • 06/05/2024 12:55:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 12:32:14 PM
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress • PR Newswire (US) • 05/16/2024 12:32:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 12:38:16 PM
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) • PR Newswire (US) • 05/15/2024 12:38:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:16:53 PM
Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/13/2024 02:53:22 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:30:14 AM
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 05/13/2024 11:30:00 AM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:30:38 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:30:13 PM
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin • PR Newswire (US) • 05/09/2024 12:30:00 PM
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast • PR Newswire (US) • 05/08/2024 12:45:00 PM

More MBRX News

InvestorsHub NewsWire

FEATURED POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • Aug 1, 2024 9:28 AM

Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM

VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM

Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM

Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM

Kona Gold Beverage Significantly Reduces Debt from Multiple Holders • KGKG • Jul 31, 2024 9:00 AM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover